A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 PatientsHubert Lau, Chia‐Sui Kao, Sean R. Williamson et al.|The American Journal of Surgical Pathology|2019Cited by 121
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerMohamed A. Gouda, Funda Meric‐Bernstam, Martin H. Voss et al.|ESMO Open|2025Cited by 54